- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00795821
A Study in Adult Patients With Major Depressive Disorder
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, C1425AHQ
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
La Plata, Argentina, 1900
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Helsinki, Finland, 00530
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Oulu, Finland, 90100
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tampere, Finland, 33100
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Turku, Finland, 20100
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Belchatow, Poland, 97-400
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Bialystok, Poland, 18-879
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Gdansk, Poland, 80 282
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Gorlice, Poland, 38-300
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Leszno, Poland, 64-100
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Lublin, Poland, 20-015
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Torun, Poland, 87-100
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tuszyn, Poland, 95-080
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Kazan, Russian Federation, 420012
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Rostov-On-Don, Russian Federation, 344010
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Saint Petersburg, Russian Federation, 191025
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tomsk, Russian Federation, 634014
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35226
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72223
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
California
-
Beverly Hills, California, United States, 90210
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Cerritos, California, United States, 90703
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Colorado
-
Denver, Colorado, United States, 80239
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Connecticut
-
Hamden, Connecticut, United States, 06518
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Florida
-
North Miami, Florida, United States, 33161
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Orlando, Florida, United States, 32806
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
West Palm Beach, Florida, United States, 33407
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Smyrna, Georgia, United States, 30080
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Maryland
-
Baltimore, Maryland, United States, 21208
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
New Jersey
-
Willingboro, New Jersey, United States, 08046
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Oregon
-
Portland, Oregon, United States, 97210
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Texas
-
San Antonio, Texas, United States, 78229
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Washington
-
Bellevue, Washington, United States, 98007
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults age 18-65 years
- Meet criteria for major depressive disorder (MDD) as defined by Diagnostic and Statistical Manual of Mental Disorders-fourth edition-text revision (DSM-IV-TR) criteria without psychotic features
- Women of child-bearing potential must test negative for pregnancy and agree to use a reliable method of birth control
- Grid 17-item Hamilton Rating Scale for Depression (GRID-HAMD17) total score ≥18 at Visit 1 and Visit 2
- Clinical global impressions of severity (CGI-S) score ≥4 at Visit 1 and Visit 2
Exclusion Criteria:
- Are currently involved in or discontinued within the last 30 days from a clinical trial involving an off-label use of an investigational drug
- Have previously completed or withdrawn from this study or any other study investigating LY2216684
- Have had or currently have any additional ongoing DSM-IV-TR Axis 1 condition other than MDD
- Have had any anxiety disorder preceding the onset of depression that was considered the primary diagnosis within 1 year of Visit 1
- Have an Axis II disorder that would interfere with protocol compliance
- Have a current or previous diagnosis of Bipolar I or II, psychotic depression, schizophrenia, or other psychotic disorder
- Have a history of substance abuse within the past 1 year
- Women who are pregnant or breast-feeding
- Have had a lack of response of the current depressive episode to 2 or more adequate courses of antidepressant therapy, or in the judgment of the investigator, considered to have treatment-resistant depression
- Participants who are judged to be at serious suicidal risk
- Have a serious or unstable medical illness
- Have any diagnosed medical condition which could be exacerbated by noradrenergic agents including unstable hypertension, unstable heart disease, tachycardia or tachyarrhythmia, narrow angle glaucoma, or urinary hesitation or retention
- Have received treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to Visit 1
- Have a history of severe allergies to more than 1 class of medication or multiple adverse drug reactions
- Have a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or psychosurgery within the last year
- Have a history of any seizure disorder (other than febrile seizures)
- Require psychotropic medication other than sedative/hypnotic medication for sleep
- Have a thyroid stimulating hormone (TSH) level outside the established reference range.
- Are taking or have received treatment with any excluded medication within 7 days prior to Visit 2
- Initiation or change in intensity of psychotherapy or other non-drug therapies within 6 weeks prior to enrollment
- A positive urine drug screen for any substance of abuse at Visit 1
- Have initiated or discontinued hormone therapy within the previous 3 months prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LY2216684
10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug. 1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of acute treatment phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62). |
Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
|
PLACEBO_COMPARATOR: Placebo
10-week Acute Treatment Phase: 3 tablets QD for 10 weeks 1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684 dose; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62). |
Dose: 3 tablets QD for 10 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 10
Time Frame: Baseline, Week 10
|
The MADRS measured severity of depressive mood symptoms.
The 10-item checklist rating scale was 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
|
Baseline, Week 10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline (Week 10) in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 62
Time Frame: Baseline (Week 10), Week 62
|
The MADRS measured severity of depressive mood symptoms.
The 10-item checklist rating scale was 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment at Week 10
Time Frame: Baseline, Week 10
|
The SDS was completed by the participant and used to assess the effect of the participant's symptoms on their work/social/family life.
Total of these 3 items=Global Functional Impairment score; scores ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life.
Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in Sheehan Disability Scale (SDS) Global Functional Impairment at Week 62
Time Frame: Baseline (Week 10), Week 62
|
The SDS was completed by the participant and used to assess the effect of the participant's symptoms on their work/social/family life.
Total of these 3 items=Global Functional Impairment score; scores ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life.
Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10
Time Frame: Baseline, Week 10
|
CGI-S measured severity of depression at the time of assessment.
Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).
Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 62
Time Frame: Baseline (Week 10), Week 62
|
CGI-S measured severity of depression at the time of assessment.
Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).
Least Squares (LS) Means were adjusted for investigator, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in the 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) at Week 10
Time Frame: Baseline, Week 10
|
The QIDS-SR16 was a 16-item participant-rated measure of depressive symptomatology.
The total score ranged from 0 to 27, with higher scores indicative of greater severity.
Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in the 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) at Week 62
Time Frame: Baseline (Week 10), Week 62
|
The QIDS-SR16 was a 16-item participant-rated measure of depressive symptomatology.
The total score ranged from 0 to 27, with higher scores indicative of greater severity.
Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) at Week 10
Time Frame: Baseline, Week 10
|
The CPFQ was a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being.
It assessed motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity.
Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent); total score ranged from 7 to 42.
Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) at Week 62
Time Frame: Baseline (Week 10), Week 62
|
The CPFQ was a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being.
It assessed motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity.
Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent); total score ranged from 7 to 42.
Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in the EuroQol Questionnaire-5 Dimension (EQ-5D) United States (US) Index Score at Week 10
Time Frame: Baseline, Week 10
|
EQ-5D was a generic, multidimensional, health-related, quality of life (Qol) instrument allowing participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and mood.
A single score between 1 and 3 was generated for each domain.
For each participant, the outcome rating on the 5 domains was mapped to a single index through an algorithm.
The index ranged between 0 and 1, with the higher score indicating a better health state perceived by the participant.
Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in the EuroQol Questionnaire-5 Dimension (EQ-5D) United States (US) Index Score at Week 62
Time Frame: Baseline (Week 10), Week 62
|
EQ-5D was a generic, multidimensional, health-related, quality of life (Qol) instrument allowing participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, mood.
Single score between 1 and 3 was generated for each domain.
For each participant, outcome rating on the 5 domains was mapped to a single index through an algorithm.
The index ranged between 0 and 1, with higher score indicating a better health state perceived by the participant.
Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Average Score at Week 10
Time Frame: Baseline, Week 10
|
The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much).
Average Score=mean of Items 1-5, 7-12, 14, and 16.
Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Average Score at Week 62
Time Frame: Baseline (Week 10), Week 62
|
The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much).
Average Score=mean of Items 1-5, 7-12, 14, and 16.
Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Experience Average Score at Week 10
Time Frame: Baseline, Week 10
|
The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much).
Fatigue Experience Average Score=mean of Items 1 to 5, and 7. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Experience Average Score at Week 62
Time Frame: Baseline (Week 10), Week 62
|
The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much).
Fatigue Experience Average Score=mean of Items 1-5, and 7. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Impact Average Score at Week 10
Time Frame: Baseline, Week 10
|
The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much).
Fatigue Impact Average Score=mean of Items 8-12, 14, and 16.
Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Impact Average Score at Week 62
Time Frame: Baseline (Week 10), Week 62
|
The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much).
Fatigue Impact Average Score=mean of Items 8-12, 14, and 16.
Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in the Brief Fatigue Inventory (BFI) Global Total Score at Week 10
Time Frame: Baseline, Week 10
|
The BFI was a participant-rated scale consisting of 9 items: 3 items assessed severity of fatigue at its "worst," "usual," and "now" during normal waking hours: 0=no fatigue to 10=fatigue as bad as you can imagine; 6 items assessed the degree to which fatigue has interfered with different aspects of the participant's life during the past 24 hours: 0=does not interfere to 10=completely interferes.
The BFI Global Total Score was the mean of the 9 item scores and ranged from 0 to 10. Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in Brief Fatigue Inventory (BFI) Global Total Score at Week 62
Time Frame: Baseline (Week 10), Week 62
|
The BFI was a participant-rated scale consisting of 9 items: 3 items assessed severity of fatigue at its "worst," "usual," and "now" during normal waking hours: 0=no fatigue to 10=fatigue as bad as you can imagine; 6 items assessed the degree to which fatigue has interfered with different aspects of the participant's life during the past 24 hours: 0=does not interfere to 10=completely interferes.
The BFI Global Total Score was the mean of the 9 item scores and ranged from 0 to 10. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in the Visual Analogue Scale for Fatigue (VAS-F) Overall Severity and Interference With Daily Activities Scores at Week 10
Time Frame: Baseline, Week 10
|
The VAS-F was a self-rated assessment with 2 items.
For the Overall Severity of Fatigue item, the participant placed a vertical mark on a 100-millimeter (mm) line between 2 anchors (0=not at all to 100=as severe as I can imagine).
For the Interference With Daily Activities Due to Fatigue item, the participant placed a vertical mark on a 100 mm line between 2 anchors (0=not at all to 100=complete disability [unable to do any activities]).
Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in the Visual Analogue Scale for Fatigue (VAS-F) Overall Severity and Interference With Daily Activities Scores at Week 62
Time Frame: Baseline (Week 10), Week 62
|
The VAS-F was a self-rated assessment with 2 items.
For the Overall Severity of Fatigue item, the participant placed a vertical mark on a 100-millimeter (mm) line between 2 anchors (0=not at all to 100=as severe as I can imagine).
For the Interference With Daily Activities Due to Fatigue item, the participant placed a vertical mark on a 100 mm line between 2 anchors (0=not at all to 100=complete disability [unable to do any activities]).
Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Percentage of Participants Reporting Resource Utilization at Week 10
Time Frame: Baseline through Week 10
|
The Resource Utilization form assessed the frequency and type of medical services that participants have used within the last year, or since the last visit.
Resources reported by at least 5% of participants in either treatment group were provided.
|
Baseline through Week 10
|
Percentage of Participants Reporting Resource Utilization at Week 62
Time Frame: Baseline (Week 10) through Week 62
|
The Resource Utilization form assessed the frequency and type of medical services that participants have used within the last year, or since the last visit.
Resources reported by at least 5% of participants in either treatment group were provided.
|
Baseline (Week 10) through Week 62
|
Percentage of Participants With Suicidal Ideation, Behavior, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 10
Time Frame: Baseline through Week 10
|
C-SSRS scale captured occurrence, severity, and frequency of suicide-related thoughts and behaviors.
Number of participants with suicidal ideation, behavior, and acts were provided.
Suicidal ideation=a "yes" answer to any 1 of 5 suicidal ideation questions (including wish to be dead) and 4 different categories of active suicidal ideation.
Suicidal behavior=a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide.
Suicidal act=a "yes" answer to actual attempt or completed suicide.
|
Baseline through Week 10
|
Percentage of Participants With Suicidal Ideation, Behavior, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 62
Time Frame: Baseline (Week 10) through Week 62
|
C-SSRS scale captured occurrence, severity, and frequency of suicide-related thoughts and behaviors.
Number of participants with suicidal ideation, behavior, and acts were provided.
Suicidal ideation=a "yes" answer to any 1 of 5 suicidal ideation questions (including wish to be dead) and 4 different categories of active suicidal ideation.
Suicidal behavior=a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide.
Suicidal act=a "yes" answer to actual attempt or completed suicide.
|
Baseline (Week 10) through Week 62
|
Mean Change From Baseline in Supine Systolic and Diastolic Blood Pressure at Week 10
Time Frame: Baseline, Week 10
|
Blood pressure was collected while the participant was in the supine position.
Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in Supine Systolic and Diastolic Blood Pressure at Week 62
Time Frame: Baseline (Week 10), Week 62
|
Blood pressure was collected while the participant was in the supine position.
Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Mean Change From Baseline in Supine Pulse at Week 10
Time Frame: Baseline, Week 10
|
Pulse was collected while the participant was in the supine position.
Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
|
Baseline, Week 10
|
Mean Change From Baseline (Week 10) in Supine Pulse at Week 62
Time Frame: Baseline (Week 10), Week 62
|
Pulse was collected while the participant was in the supine position.
Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.
|
Baseline (Week 10), Week 62
|
Pharmacokinetic (PK) Parameter: Plasma Concentration of LY2216684
Time Frame: Baseline through Week 62
|
Blood samples collected from participants that received LY2216684 were measured to determine the plasma LY2216684 concentrations.
|
Baseline through Week 62
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11313
- H9P-MC-LNBI (OTHER: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on LY2216684
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyTerminatedAttention Deficit Hyperactivity DisorderUnited States, Canada, Taiwan, Puerto Rico
-
Eli Lilly and CompanyCompletedDepressive Disorder, MajorUnited States
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited States
-
Eli Lilly and CompanyCompletedDepressive Disorder, MajorUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedDepressive Disorder, MajorUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedDepressive Disorder, MajorUnited States, Mexico, Spain, Brazil, Chile, Lithuania, Netherlands